Go Back

Affini-T Therapeutics’ KRAS TCR T Cell Therapy Program to be Presented at the Annual Meeting of the American Society of Gene and Cell Therapy

05.03.2022

BOSTON, Mass., and SEATTLE, Wash. – May 3, 2022 – Affini-T Therapeutics, Inc., a biotechnology company unlocking the power of T cells against oncogenic driver mutations, today announced that data from its KRAS program will be presented in an oral presentation at the 25 Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT). The data from Affini-T Therapeutics will be delivered by Tijana Martinov, Ph.D. from the Greenberg Lab at Fred Hutchinson Cancer Center.

“KRAS mutations are the most prevalent oncogenic drivers in solid tumor cancers with G12V and G12D variants representing the most common substitutions within this oncogene,” said Loïc Vincent, Ph.D., Chief Scientific Officer, Affini-T Therapeutics. “We are excited that our TCR-engineered T cell therapies, designed to orchestrate a coordinated CD4 and CD8 T cell response while targeting these common mutant variants of KRAS, show promising preclinical safety and efficacy profiles that support clinical development for solid tumor patients with KRAS mutations who have high unmet medical needs.”

Presentation details are as follows:

Title: Preclinical Development of Safe and Effective T Cell Receptors Specific for Mutant KRAS G12V and G12D Peptides
Presenting Author: Tijana Martinov, Ph.D
Abstract Number: 103
Poster Number: 186b
Poster Session Title: Cell-Based Cancer Immunotherapies I
Date & Time:  Monday, May 16, 2022 at 4:45pm – 5:00pm ET

About Affini-T Therapeutics
Affini-T is unlocking the power of T cells and targeting core oncogenic drivers to develop potentially curative therapies for solid tumor cancers. Our differentiated cell therapy platform harnesses state-of-the-art engineering and synthetic biology capabilities to target even the most devastating cancer-driving mutations, beginning with KRAS. We leverage these tools to optimize T cell functions and rewrite the rules of the solid tumor microenvironment, enabling the potential for sustained clinical outcomes in patients. Building on the world-class innovation inherent in our leadership team, founders and technologies, we are powered to develop transformational medicines that last. Follow us on LinkedIn and Twitter.

Contacts:
Media Contact
Ian Stone
Canale Communications
Ian.stone@canalecomm.com
619-849-5388

Investor Contact
IR@affinittx.com

---

Go Back